GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Ilex Medical ILX.TA · ILA

Health Care · Tel Aviv · 🇮🇱 Israel

Compare

4,710.00

+0.13%

Close of 9 Nov 2026, in ILA

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in ILS, from our data supplier.

FY2024

Revenue

ILS 920.4m

FY2015FY2024

Net income

ILS 39.0m

FY2015FY2024

Free cash flow

—

FY2015FY2024

Shareholders' equity

ILS 646.5m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
RevenueILS 920.4mILS 916.2mILS 872.5mILS 1.06bnILS 946.5mILS 634.0mILS 601.1mILS 553.7mILS 518.9mILS 497.5m
Gross profitILS 218.6mILS 230.6mILS 289.2mILS 386.2mILS 274.2mILS 195.6mILS 185.6mILS 148.7mILS 139.4mILS 149.6m
Research and developmentILS 7.2mILS 6.5mILS 8.8mILS 7.8mILS 8.1mILS 7.2mILS 7.4mILS 7.0mILS 7.5m—
Operating incomeILS 65.9mILS 82.4mILS 141.5mILS 257.1mILS 150.4mILS 82.9mILS 75.8mILS 53.4mILS 50.0mILS 54.2m
Net incomeILS 39.0mILS 50.9mILS 102.1mILS 197.5mILS 120.6mILS 60.3mILS 47.0mILS 37.4mILS 27.6mILS 31.1m
Diluted earnings per share3.484.549.0517.5011.246.004.683.732.763.10

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assetsILS 994.1mILS 1.02bnILS 899.2mILS 875.1mILS 779.2mILS 581.9mILS 533.4mILS 484.9mILS 487.6mILS 481.6m
Cash and short-term investmentsILS 233.6mILS 213.3mILS 224.2mILS 282.9mILS 173.7mILS 87.0mILS 89.3mILS 92.4mILS 77.2mILS 94.7m
Total liabilitiesILS 347.6mILS 392.6mILS 286.1mILS 299.5mILS 335.7mILS 359.1mILS 343.6mILS 322.6mILS 346.5mILS 361.9m
DebtILS 51.3mILS 48.3mILS 51.6mILS 58.7mILS 66.7mILS 96.9mILS 70.2mILS 80.7mILS 100.6mILS 106.1m
Shareholders' equityILS 646.5mILS 623.5mILS 613.1mILS 575.6mILS 443.5mILS 222.8mILS 189.8mILS 162.3mILS 141.1mILS 119.7m
Shares outstanding11m11m11m11m11m10m10m10m10m10m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations—ILS 80.4mILS 69.7mILS 270.7mILS 182.4mILS 84.9mILS 58.6mILS 76.0mILS 12.8mILS 45.2m
Capital spending—−ILS 52.2m−ILS 28.4m−ILS 42.6m−ILS 46.4m−ILS 31.3m−ILS 24.5m−ILS 21.1m−ILS 14.7m−ILS 25.2m
Free cash flow—ILS 28.3mILS 41.4mILS 228.0mILS 136.0mILS 53.6mILS 34.1mILS 54.8m−ILS 1.9mILS 20.0m
Dividends paid—−ILS 21.4m−ILS 60.0m−ILS 60.0m—−ILS 25.0m−ILS 18.0m−ILS 15.0m−ILS 10.0m—

Latest quarters

By quarter end

Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024Dec 2023
RevenueILS 227.6mILS 219.3mILS 238.3mILS 221.5mILS 240.1mILS 218.9mILS 239.9mILS 284.1m
Gross profitILS 52.0mILS 49.6mILS 54.9mILS 51.2mILS 57.5mILS 50.7mILS 56.9mILS 64.8m
Operating incomeILS 14.8mILS 11.7mILS 15.6mILS 17.4mILS 18.6mILS 10.9mILS 19.8mILS 24.4m
Net incomeILS 11.0mILS 16.9mILS 9.1mILS 6.6mILS 13.0mILS 5.5mILS 13.9mILS 22.4m
Diluted earnings per share0.981.510.810.591.160.491.252.01
Total assetsILS 969.9mILS 947.3mILS 987.1mILS 994.1mILS 1.01bnILS 997.7mILS 999.5mILS 1.02bn
Cash and short-term investmentsILS 239.9mILS 246.6mILS 222.5mILS 233.6mILS 181.0mILS 261.8mILS 240.1mILS 213.3m
DebtILS 36.6mILS 33.7mILS 36.4mILS 38.8mILS 41.8mILS 41.6mILS 39.4mILS 36.4m
Shareholders' equityILS 673.7mILS 660.4mILS 646.4mILS 646.5mILS 641.8mILS 628.8mILS 621.8mILS 623.5m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-4.6%7.7%7.8%
Operating income-36.5%-4.5%4.6%
Net income-41.8%-8.3%5.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin24.5%29.8%29.8%29.4%
Operating margin8.1%14.5%14.6%13.3%
Net margin4.9%10.3%10.7%9.2%

Valuation history

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Price to earnings21.512.910.69.310.913.911.314.415.211.3
Price to sales0.90.71.21.71.41.30.91.00.80.7

Dividends and splits

Per share, in the currency the company pays

Paid for 5 years. Last went ex-dividend on 10 Apr 2026.

FY2025FY2024FY2023FY2022FY2021FY2019FY2018FY2017
Paid in the year1.221.3651.9175.3195.3192.4911.7941.495

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.